20 In adults 40 to 75 years old without diabetes mellitus and 10-year risk of 7.5% to 19.9% (intermediate risk), riskenhancing factors favor initiating statin therapy (see No. 7). Riskenhancing factors include family history of premature ASCVD; persistently elevated LDL-C levels ≥160 mg/dL (≥4.1 mmol/L); metabolic syndrome; chronic kidney disease; history of preeclampsia or premature menopause (age <40 years); chronic inflammatory disorders (eg, rheumatoid arthritis, psoriasis or chronic HIV); high-risk ethnic groups (e.g., South Asian); persistent elevations of triglycerides ≥175 mg/dL (≥1.97 mmol/L); and, if measured in selected individuals, apolipoprotein B ≥130 mg/dL, highsensitivity C-reactive protein ≥2.0 mg/L, ankle-brachial index <0.9 and lipoprotein (a) ≥50 mg/dL or 125 nmol/L, especially at higher values of lipoprotein (a). Risk-enhancing factors may favor statin therapy in patients at 10-year risk of 5 to 7.5% (borderline risk). In adults 40 to 75 years old without diabetes mellitus and with LDL-C levels ≥70 mg/dL to 189 mg/dL (≥1.8-4.9 mmol/L), at a 10-year ASCVD risk of ≥7.5% to 19.9%, if a decision about statin therapy is uncertain, consider measuring coronary artery calcium. If CAC is zero, treatment with statin therapy may be withheld or delayed, except in persons who smoke tobacco, people with diabetes mellitus and those with a strong family history of premature ASCVD. A CAC score of 1 to 99 favors statin therapy, especially in those ≥55 years old. For any patient, if the CAC score is ≥100 Agatston units or ≥75th percentile, statin therapy is indicated unless otherwise deferred by the outcome of clinician–patient risk discussion. Assess adherence and percentage response to LDL-C–lowering medications and lifestyle modifications with repeat lipid measurement four to 12 weeks after statin initiation or dose adjustment, repeated every three to 12 months as needed. Define responses to lifestyle and statin therapy by percentage reductions in LDL-C levels compared with baseline. In very-high-risk ASCVD patients, triggers for adding non-statin drug therapy are defined by threshold LDL-C levels ≥70 mg/ dL (≥1.8 mmol/L) on maximal statin therapy (see No. 3). 8 9 10 Check Out Patient Education Resources at heart.org/lpa
RkJQdWJsaXNoZXIy MjI2NjI=